Photo from academic.microsoft.com
Chronic pain presents a difficult clinical challenge because of the limited efficacy, the limiting adverse‐effect profile or the abuse potential of current analgesic options. Cebranopadol is a novel new agent… Click to show full abstract
Chronic pain presents a difficult clinical challenge because of the limited efficacy, the limiting adverse‐effect profile or the abuse potential of current analgesic options. Cebranopadol is a novel new agent in clinical trials that combines dual agonist action at opioid and nociceptin/orphanin FQ peptide (NOP) receptors. It is the first truly unique, centrally acting analgesic in several years. We here review the basic and clinical pharmacology of cebranopadol.
Keywords:
opioid nop;
dual opioid;
novel dual;
cebranopadol novel;
opioid
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!